We have some news from Moderna's vaccine candidate.
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases and member of the White House Coronavirus Task Force, explained why he remains "cautiously optimistic" around Moderna and the other vaccine candidates.
But let's break down the news more: Moderna said the trial’s primary aim will be to prevent the coronavirus, while secondary goals include prevention of severe cases of the disease that require hospitalization, and prevention of infection by SARS-CoV-2, the virus that causes COVID-19
The company said it selected the 100-microgram dose of the vaccine for the late-stage study to maximize the immune response and minimize adverse reactions.
At that dose level, Moderna is on track to deliver about 500 million doses per year, and possibly up to 1 billion doses per year, starting in 2021 from the company's internal U.S. manufacturing site and strategic collaboration with Swiss drugmaker Lonza
The company said it has made enough vaccine to start the Phase III trial. Moderna said it intended to enroll 600 healthy participants across two groups of adults ages 18 to 54 years, and older adults ages 55 years and above.
Dr. Fauci said that this trial is a "large trial" and it will help to "determine efficacy."
"And hopefully, after a few months, once we get into the fall and then the winter, we'll have an answer on whether or not the vaccine does or doesn't work," Dr. Fauci told TheStreet.
Watch the clip above for more from Dr. Fauci.
You can follow Katherine Ross on Twitter at @byKatherineRoss.
Watch More of the Latest Videos on TheStreet and Jim Cramer
- Jim Cramer: Broadcom Is 'Greatest Value' of Semiconductor Stocks
- Jim Cramer: Advice for Investors Learning About the Stock Market
- TheStreet Explains: What Is Value Versus Growth in Stocks?
- How Magic Johnson Became the Business Icon He Is Today
- C-Suite: Why the Nikola Executive Team Is Taking Salaries of $1